Background: Survey data has suggested a gap between individuals willing to participate in a clinical trial and those who enroll. Clearer research must be done to better understand this discrepancy and the accessibility of patient-desired information, such that steps can be identified to assist sponsors in empowering patients to drive their own clinical trial search journey. Methods: Patients, sponsors, and health care professionals were engaged through surveys and advisory boards to determine the ideal information for sponsors to provide during a clinical trial search. Public registries were analyzed to assess availability of basic investigator and site contact location information. Results: Data reiterated the need for patients to have easy and unambiguous methods of connecting with the clinical trial site. Analysis of data on registries prove that sponsors have the opportunity to better utilize contact information on databases to enable a patient's clinical trial search journey. Conclusions: More robust disclosure of site location and contact details on public registries could lay the foundation for a more user-friendly clinical trial search. Allowing sites autonomy in site contact methods while promoting accessibility will facilitate the connection of interested patients with appropriate trial opportunities.
Background
Searching for a clinical trial can be a complex process for patients, caregivers, and health care professionals (HCPs). 1 Providing simple and effective tools to facilitate this search may improve engagement with clinical research and overall development of innovative therapeutic treatments and cures for disease. 2 The 2015 Center for Information and Study on Clinical Research Participation (CISCRP) Perceptions and Insights Study reported that 80% of respondents were somewhat to very willing to participate in a clinical trial; of those with a health condition, willingness to participate ranged from 93% to 96% depending upon severity of disease. Despite 55% of global respondents valuing the physical location of the clinical research center as very important in their decision to participate, 3 it is not clear how often the location or contact details of individual investigative sites participating in a clinical trial are made public.
Clinical trial registries such as ClinicalTrials.gov, the European Clinical Trials Register (EU CTR), and the World Health Organization International Clinical Trials Registry Platform (ICTRP) provide the public with information regarding upcoming, ongoing, and completed clinical trials conducted throughout the world. Generally considered to be one of the most trusted sources of information for individuals seeking clinical trial information, ClinicalTrials.gov provides the public with information on 238 400þ studies from 196 countries in the world (March 8, 2017) . 4 If utilized by study sponsors to their potential, Clinical Trials.gov and other public registries could serve as a key enabler for patients and their HCPs worldwide to connect directly with clinical trial site locations of interest to them.
Although many opportunities exist to better connect patients and their HCPs with suitable clinical trials, 5 TransCelerate Biopharma Inc (TransCelerate) identified public disclosure of individual site contact information as a practical advance toward this goal that could be accomplished in the short term. Our initial proposal, as outlined in this article, is for sponsors to partner with investigative sites across the globe to ensure clinical trials posted to registries include a transparent and unambiguous method of contact for each participating site location.
Methods
TransCelerate conducted primary research to better understand information important to patients when considering or searching for a clinical trial, HCP familiarity and experience with clinical trial information and referrals, and current and possible future practices relating to accessibility of site contact information. Surveys and/or advisory boards with patients, sites, HCPs, and sponsors were designed by TransCelerate. An assessment of site-specific information available on ClinicalTrials.gov was also performed.
Patient Survey
The 52-question patient survey was conducted in August-September of 2016 and distributed online globally to patients and caregivers with the support of CISCRP, Clariness, Center-Watch, and TransCelerate through outreach efforts within their patient/caregiver communities. Participants represented 36 countries across North America, Latin/South America, Europe, Asia Pacific, and Africa. Four countries (US, Canada, Germany, and Australia) contributed more than 250 respondents each. There were 3045 respondents who self-identified as patients (73.8%), caregivers (7.6%), or "other" (18.6%). Fifty-eight percent (1762/3045) of the respondents were 55 years of age or older. This was a convenience sample that utilized Internet communication, and as such, findings may not be representative of the opinions of the entire population.
Sponsor Survey
The sponsor survey was conducted in August-September of 2016 and distributed online to 18 TransCelerate member companies. Thirteen companies (72%) responded. The responding companies submitted responses to a third-party consultant who blinded and aggregated the survey results. TransCelerate members would generally be considered large in size relative to all clinical trial sponsors. To the extent that a sponsor's organizational size may affect its practices concerning the subject matter covered in the survey, the responses may not represent the practices of the entire industry.
HCP Survey
The HCP survey was distributed and promoted by the SERMO survey platform via a Pulse Opinion Research Poll available between August 1 and August 6, 2016. A total of 462 replies were received from 7 countries and 6 specialty categories, including General Practitioner/Family Practice (37%), Nursing (28%), Neurology (10%), Oncology (10%), Infectious Diseases (5%), and Pediatric Medicine (10%).
Analysis of Contact Information on ClinicalTrials.gov
ClinicalTrials.gov was analyzed for overall availability of contact details for interventional trials. This included analysis of study-specific central contact details, defined as a single point of contact for any location of the study, as well as facility contact details, defined as contact information specific to a clinical trial site.
A total of 211 437 trials with National Clinical Trial Identification (NCT IDs), consisting of 1 633 395 unique sites, were analyzed. All available trial data were downloaded from https://clinicaltrials.gov/ on March 24, 2016, and loaded into a relational database. Reports were generated using a visual data analysis tool. Of these 211 437 trials, 49 520 were multicenter interventional trials initiated between 1996 and 2015, consisting of 1 204 048 unique sites. Trials with >10 000 patients enrolled, trials that lacked a study start date, and single-site trials were excluded so that analyzed trials could be compared in a similar fashion. Of these 49 520 trials, 10 487 were categorized as "recruiting" or "not yet recruiting," consisting of 216 478 unique sites.
Patient Advisory Board (PAB)
TransCelerate commissioned a CISCRP-facilitated PAB in August (online) and October (in person) of 2016. Ten patients, patient advocates, or caregivers, aged 21 to 70 years, from the US (6), Canada (1), Europe (2), and Africa (1) participated. Half of the participants had previous trial experience. Participants represented gastrointestinal, metabolic, neurologic, oncologic, and hematologic conditions.
Site Advisory Group (SAG)
TransCelerate commissioned a Society for Clinical Research Sites (SCRS) SAG in August (online) and October (in person) of 2016. Eight investigative site professionals located in the US (6) and Europe (2) participated. Participant experience ranged across clinical trial phases, therapeutic areas, and site types such as Family Medicine, research centers, specialty clinics, and/or hospital-based facilities.
Results

Patient Survey
Results from the patient survey are shown in Table 1 . Most (74%) survey respondents reported that neither they nor the person they cared for had any experience with any clinical trial. Encouragingly, 94% of respondents felt it was somewhat to very important to be aware of trials conducted in their community; however, a large majority (79%) were unaware of clinical trials recruiting for their condition of interest. The Internet was a key means of staying aware of and searching for clinical trials. This was not dependent on current or past clinical trial experience. Although a relatively smaller portion (16%) used a registry/database maintained by their government, data supplied to other Internet sources often originate from registry/ database sources.
Seventy-six percent of respondents reported that site contact information was the most important information to have before participating in a clinical trial. Similarly, 72% of respondents indicated willingness to contact a clinical trial location directly. Of these respondents, 65% preferred to contact the site via email followed by 33% preferring to contact the site via telephone. Also, 92% (1972/2152) of all respondents would be interested in registering their contact information on a secure website to be notified when a trial opportunity arises.
It should be noted that, due to the online survey method involved, the respondents already had Internet access; therefore, site contact preferences could be biased toward online methods.
Sponsor Survey
Responses to selected questions in the sponsor survey are shown in Table 2 . All respondents had standard operating procedures (SOPs) for disclosing clinical trial information on public registries and most (62%) reported that their SOP offered registry-specific guidance.
Although registries such as ClinicalTrials.gov allow for posting of site names, addresses, and contact information (phone number/email address), most (77%) responding companies did not post site-specific contact information. Three responding companies "sometimes" posted this information based on the recruitment status of the trial, geographic location, contractual agreement with the site, and phase of the study. Fewer than half (46%) of the responding companies asked each site to disclose site information publicly. Interestingly, of those who requested the agreement of sites to disclose this information publicly "always" or "sometimes," half still "never" post facility contact information for each individual clinical trial location to Clinical-Trials.gov. Those who "sometimes" post this information cited contractual agreements with sites, geographic location of sites, phase of trial (eg, I, II, III, IV), and status of trial (eg, active, recruiting, not recruiting) as factors that impact the decision on whether or not to post the information.
HCP Survey
Results of the HCP survey are shown in Table 3 . Although 86% of respondents felt very or somewhat positive toward clinical research, fewer than 50% had discussed clinical trials as an option with a patient or referred a patient for participation in a clinical trial. Even fewer had referred a patient directly to a specific clinical trial site. Greater education regarding methods to search for clinical trials is needed based on the low percentage (<40%) of respondents who knew where to find information on clinical trials based on geographic location. Knowledge of where to find information on clinical trials based on geography was particularly low among HCPs without clinical research experience (27%, 75/276). Approximately 40% indicated that lack of information regarding clinical trials in their geographic area prevented them from recommending clinical trial participation to a patient.
Analysis of Contact Information on ClinicalTrials.gov
Of the ClinicalTrials.gov trials analyzed with a status of "recruiting" or "not yet recruiting," 80% had disclosed email addresses for central contacts and 78% a central phone number (Table 4 ). These central contact details allow only one point of inquiry for the overall clinical trial as opposed to individual inquiry to specific investigative sites. Only 39% of clinical trials listed some form of contact details (phone number and/or email) associated with specific investigative site locations. This consisted of 34% of unique sites with a phone number and 23% with email listed (Table 4) . Incremental increases in such information occurred during the 18-year period of analysis (data not shown).
Country-level analysis revealed clear trends in disclosure of facility/site contact details (data not shown). For example, the US, China, France, and Canada had some of the highest percentages of sites with available contact information. Conversely, the percentage was particularly low in Japan, Brazil, and Hungary.
Patient Advisory Board (PAB)
Participants in the PAB voiced awareness of clinical trials as potential options and felt it was important for patients to be able to search for and identify clinical trials for which they may be eligible. A general lack of knowledge within the broader patient community regarding where to find clinical trial resources or information was cited as an issue. Those who had searched for clinical trials did so using general Internet searches and registries but felt these sources were difficult to navigate and fell short of expectations with regard to usefulness, personalization, and clarity. PAB participants were generally willing to contact a trial site directly and to share personal details in order to gain access to suitable clinical trial opportunities but expressed concern about the perceived frustrations and time delays potentially involved with contacting a central call center or email. When faced with the option to pursue a particular clinical trial, participants preferred contacting a specific site location of interest directly and, at their discretion, involving their primary/specialty care physician in the process. Participants also expressed the potential for significant disappointment upon hearing they are not eligible for a particular clinical trial, emphasizing the importance of research stakeholders involved in the process taking action to mitigate this perceived setback.
Site Advisory Group (SAG)
Participants in the SAG expressed eagerness to facilitate contact between HCPs and available clinical trial sites to promote confidence in sites' expertise for potential referrals. Participants felt it was important for sponsors to leverage individual sites' judgment when deciding which method of contact would be most appropriate to disclose on a public registry. This position was based on several reasons, including the tendency of sites to have the most insight into their local patient population (and by extension, their preferences and available means for contact) and the varying staffing and infrastructure capabilities at a given site. Providing flexibility of site contact method on a site-by-site, and possibly study-by-study, basis would allow sites to staff appropriately based on patient population and expected inquiry volume.
Discussion
The original research presented here suggests that patients have the desire to be more informed about clinical trials in their community and that most HCPs lack this information. The majority of studies posted on ClinicalTrials.gov do not contain direct contact details for all participating investigative sites and sponsors agreed that such information is rarely disclosed. This void of available information on the specific location and contact information for enrolling clinical trial sites remains an unnecessary barrier between patients (and their health care providers) and specific clinical trial opportunities.
The clinical trial site can be key to linking patients to trials. SAG discussions and a separate global site survey conducted by SCRS (unpublished data) suggest that the investigative site community is largely supportive of efforts to provide greater links between a patient and a clinical trial site. In the SCRS survey, 91% of respondents were willing to publicly disclose site contact information to help patients find them. 3 If sponsors and sites more commonly partnered to determine the most optimal method of site contact to make available to patients and HCPs on public registries, at times on a study-by-study basis, improvements could be made to bridge existing divides between parties who have a vested interest in finding each other.
The need for increased accessibility of clinical trial information was recognized by the US Department of Health and Human Services in the Final Rule on Federal and Drug Administration Amendment Acts (FDAAA) 801 (effective January 18, 2017). This new rule expands the amount of information that sponsors are required to submit to ClinicalTrials.gov at the time of registration and results submission of a study and specifies stricter timeframes for when disclosed information must be updated. In line with concerns voiced by the PAB, the NIH stated that one of the goals of the Final Rule is to better facilitate patients' search for a clinical trial and improve their ability to access information.
Although the Final Rule mandates disclosure of specific types of information that further facilitate patient access to investigative medicines, sponsors have the opportunity to disclose additional information and/or provide additional methods of contact with global sites to address the needs and preferences of both the patient population and sites. ClinicalTrials.gov has reported more than 199 million page views per month and 76 000 unique visitors per day as of February 2017, and the platform is also used as an upstream source of data by many other registries and online services including ICTRP, Center-Watch, and Antidote. The platform's reach ensures that even small changes to disclosure of additional information could have a substantial impact.
With the goal in mind to increase availability of site contact information to better serve patients, there must also be a legitimate ability and opportunity for sites to choose how they want to be contacted by patients, HCPs, and others pursuing a trial opportunity, based on each site's unique infrastructure and circumstances. Based on the data collected from stakeholders, possible options for consideration by sponsors and sites to connect patients with sites are presented in Table 5 .
The most direct way for connecting patients to clinical trial sites would be through posting on public registries the phone numbers and email addresses of applicable site locations throughout the world. However, sites must be adequately equipped with the ability to handle patient inquiries through this method. This option may not be feasible for sites and thus, some may prefer prescreening options be used prior to direct connection to the site. In those instances, central call centers or self-service prescreening options could be implemented to better suit the particular site. Such options would require sponsors to set up and maintain an operating model for responding to inquiries about clinical trials as a first contact measure.
The goal of these options is to allow the patient, HCP, or other interested individual to use information posted on public registries to be connected directly with a site location of interest in one to two simple steps. In many cases, contact is ideally initiated in partnership between patients and their HCPs as they work together to evaluate clinical trial options. Likewise, it is up to the sponsors to discuss potential contact options with respective sites to agree which options provide patients a direct link to trial opportunities while also balancing the needs and preferences of the sites and local patient populations served. The research presented here suggests that a majority of patients (with web access) prefer email over telephone calls when making contact with sites and most patients would be interested in registering their contact information on a secure website in order to be notified when an appropriate trial opportunity becomes available. Regardless of the site contact option chosen, sponsors and sites should both take care to ensure that inquiring patients who are found not to be eligible for a particular clinical trial should be provided with an alternative option or suggested next step(s) to aid them in their continued trial search journey.
Conclusions
Although the specific options presented here may not work for every study, sponsor, or site, stakeholder surveys and advisory boards suggest that a partnership between sponsors and investigative sites across the globe to provide more robust disclosure of site location and contact details on public registries could lay the foundation for a more patient-centric clinical trial search. Future efforts should also focus on improving patients' overall user navigation through registries, making information easier to locate and understand, and making information more actionable. One of many improvement opportunities related to site location and contact details is the ability to use address details of sites to visually plot all available sites for a given study on a map, rather than requiring users to sift through lists of sites by generic postal code. This capability would also allow for additional functions, such as retrieving directions from a home location to a site location within a matter of seconds.
It is acknowledged that disclosure of site level contact and location information for large volumes of clinical trials presents a challenge for sponsors in ensuring integrity of data within clinical trial management systems and registry databases. As the landscape of the health care industry evolves, the data management systems utilized by sponsors will need to evolve. Sponsors have traditionally had difficulties staying up-to-date with satellite sites and ensuring "one version of the truth" for site details. One potential means by which sponsors can avoid this problem is through enhanced usage of site and investigator registries that could support the "mastering" of site facility data. Such registries could conceivably maintain up-todate location and contact information at the discretion of the individual site/facility, potentially even allowing for a default preferred method of contact with sites across multiple sponsors in addition to study-specific preferences on an as-needed basis.
If provided with a way to connect to a site, patients and their treating HCPs across the globe can begin to make an informed decision regarding clinical trial participation; sites have the potential to accelerate recruitment; and all stakeholders may benefit from accelerated development of novel therapeutics.
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